UY25844A1 - Modificación a cristal de una sustancia activa de medicamento - Google Patents

Modificación a cristal de una sustancia activa de medicamento

Info

Publication number
UY25844A1
UY25844A1 UY25844A UY25844A UY25844A1 UY 25844 A1 UY25844 A1 UY 25844A1 UY 25844 A UY25844 A UY 25844A UY 25844 A UY25844 A UY 25844A UY 25844 A1 UY25844 A1 UY 25844A1
Authority
UY
Uruguay
Prior art keywords
modification
crystal
crystal modification
triazol
carboxamide
Prior art date
Application number
UY25844A
Other languages
English (en)
Spanish (es)
Inventor
Martin Szelagiewicz
Walter Scherrer
Andreas Burkhard
Urs Christoph Hofmeier
Robert Portmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY25844A1 publication Critical patent/UY25844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY25844A 1997-06-10 1999-12-10 Modificación a cristal de una sustancia activa de medicamento UY25844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10

Publications (1)

Publication Number Publication Date
UY25844A1 true UY25844A1 (es) 2001-08-27

Family

ID=4209650

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25844A UY25844A1 (es) 1997-06-10 1999-12-10 Modificación a cristal de una sustancia activa de medicamento

Country Status (36)

Country Link
US (6) US6740669B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0994864B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3672575B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100409168B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1132820C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (4) AR012945A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE232852T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU725528B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR9804946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (3) CA2256015C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (2) CO4940448A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2007014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (2) CZ292481B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69813560T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK0994864T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2192779T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR07C0037I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU226107B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (2) ID27660A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL125732A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91345I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (2) MY125854A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300284I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO329314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ331370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (2) PE79799A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL191943B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT994864E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2194041C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI0994863T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (2) SK283685B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (2) TR199801630T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW403740B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY25844A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO1998056772A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA984967B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
WO2003101991A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
US8183269B2 (en) 2008-10-13 2012-05-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) * 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
AU2010290049B2 (en) * 2009-09-04 2013-09-19 Tactical Therapeutics, Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
JP2013525413A (ja) * 2010-04-30 2013-06-20 ラボラトリオス レスヴィ，エス．エル． ルフィナマイド中間体の改良された製造方法
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
FI93544C (fi) * 1985-04-18 1995-04-25 Ciba Geigy Ag Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
JPH04506967A (ja) 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー 高血圧症治療用腎選択性生成物
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU656154B2 (en) 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
DE69609314T2 (de) 1995-02-22 2001-06-13 Aventis Pharma Ltd., Tokio/Tokyo Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung
SI0918758T1 (en) * 1996-07-11 2002-10-31 Novartis Ag Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
US20010037029A1 (en) 2001-11-01
CY2007014I1 (el) 2009-11-04
WO1998056772A1 (en) 1998-12-17
IL125732A (en) 2002-12-01
TR199801630T1 (xx) 1999-06-21
CN1259127A (zh) 2000-07-05
PL191943B1 (pl) 2006-07-31
JP3672574B2 (ja) 2005-07-20
US20040167186A1 (en) 2004-08-26
CO4940448A1 (es) 2000-07-24
CY2007014I2 (el) 2009-11-04
ID27660A (id) 2001-04-19
ZA984966B (en) 1999-01-11
SI0994864T1 (en) 2003-10-31
CN1132820C (zh) 2003-12-31
PL330798A1 (en) 1999-06-07
US6740669B1 (en) 2004-05-25
NO983667L (no) 1998-12-17
KR100409168B1 (ko) 2004-01-31
ZA984967B (en) 1999-01-11
RU2194041C2 (ru) 2002-12-10
ID21014A (id) 1999-04-08
LU91345I2 (fr) 2007-09-04
KR19990087836A (ko) 1999-12-27
MY120156A (en) 2005-09-30
DE69813560D1 (de) 2003-05-22
CN1159300C (zh) 2004-07-28
AU8437198A (en) 1998-12-30
DE122007000051I2 (de) 2009-02-19
MY125854A (en) 2006-08-30
CZ253398A3 (cs) 1999-04-14
PE80999A1 (es) 1999-09-06
DE122007000051I1 (de) 2007-11-08
US20100310655A1 (en) 2010-12-09
DK0994864T3 (da) 2003-07-21
US20030125568A1 (en) 2003-07-03
ATE237599T1 (de) 2003-05-15
US20060116520A1 (en) 2006-06-01
ES2192779T3 (es) 2003-10-16
HU226107B1 (en) 2008-04-28
RU2198167C2 (ru) 2003-02-10
TW526195B (en) 2003-04-01
DE69811500T2 (de) 2004-04-01
DE69811500D1 (de) 2003-03-27
EP0994864B1 (en) 2003-04-16
HK1028242A1 (en) 2001-02-09
CZ292481B6 (cs) 2003-09-17
JP3672575B2 (ja) 2005-07-20
HU225153B1 (en) 2006-07-28
DK0994863T3 (da) 2003-05-26
NZ331370A (en) 2000-08-25
ES2197485T3 (es) 2004-01-01
KR100425656B1 (ko) 2004-05-17
NO329314B1 (no) 2010-09-27
CZ292260B6 (cs) 2003-08-13
US7750028B2 (en) 2010-07-06
LU91345I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-12-31
AR012945A1 (es) 2000-11-22
NO983666L (no) 1998-12-17
HUP0002113A3 (en) 2002-09-30
JP2000516259A (ja) 2000-12-05
HUP0000798A2 (hu) 2000-10-30
AU8437298A (en) 1998-12-30
SK109498A3 (en) 1998-12-02
HK1028031A1 (en) 2001-02-02
ATE232852T1 (de) 2003-03-15
PT994864E (pt) 2003-07-31
TW403740B (en) 2000-09-01
EP0994864A1 (en) 2000-04-26
PL330764A1 (en) 1999-05-24
NZ331371A (en) 2000-08-25
CN1572789A (zh) 2005-02-02
NL300284I2 (nl) 2007-11-01
KR19990087835A (ko) 1999-12-27
CA2614926A1 (en) 1998-12-17
US8076362B2 (en) 2011-12-13
AU725517B2 (en) 2000-10-12
CA2256013A1 (en) 1998-12-17
NO329315B1 (no) 2010-09-27
AR061004A2 (es) 2008-07-30
HUP0000798A3 (en) 2000-10-30
IL125732A0 (en) 1999-04-11
BR9804946A (pt) 1999-08-24
US6455556B2 (en) 2002-09-24
HUP0002113A2 (hu) 2001-02-28
EP0994863B1 (en) 2003-02-19
IL125733A0 (en) 1999-04-11
SK283685B6 (sk) 2003-12-02
BR9804947A (pt) 1999-08-24
AR012946A1 (es) 2000-11-22
CZ253498A3 (cs) 1999-04-14
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
NO983666D0 (no) 1998-08-11
FR07C0037I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-08-17
CN1298708C (zh) 2007-02-07
CA2256015A1 (en) 1998-12-17
PE79799A1 (es) 1999-09-03
AU725528B2 (en) 2000-10-12
IL125733A (en) 2002-12-01
SK109398A3 (en) 1998-12-02
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
TR199801631T1 (xx) 1999-06-21
CA2614926C (en) 2010-02-09
AR061005A2 (es) 2008-07-30
CA2256013C (en) 2007-10-16
HK1028241A1 (en) 2001-02-09
CN1217716A (zh) 1999-05-26
FR07C0037I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-05-16
SI0994863T1 (en) 2003-08-31
CO4940452A1 (es) 2000-07-24
DE69813560T2 (de) 2004-02-05
PL192114B1 (pl) 2006-08-31
EP0994863A1 (en) 2000-04-26
JP2000516258A (ja) 2000-12-05
CA2256015C (en) 2008-06-03

Similar Documents

Publication Publication Date Title
UY25844A1 (es) Modificación a cristal de una sustancia activa de medicamento
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
ATE185058T1 (de) Vom patient betätigtes orthopädisches gerät
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
AR003116A1 (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos
ES2093979T3 (es) Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino)fenilacetico y su procedimiento de preparacion.
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
ATE49962T1 (de) Taxal-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ES2194935T3 (es) Preparados estables de transglutaminasa y procedimiento para su preparacion.
ES2163076T3 (es) Composiciones antitumorales que contienen derivados del taxano.
ES8505405A1 (es) Un procedimiento para producir un activador de plasminogeno purificado.
DE69106586D1 (de) Verwendung von Baclofen zur Herstellung von Arzneimitteln zur Behandlung von Angina pectoris.
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
ES2067874T3 (es) Derivados de acetamida.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
PT101725A (pt) Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem
CY1111509T1 (el) Ενωσεις με ιδιοτητες απελευθερωσης αυξητικης ορμονης
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
ES2044970T3 (es) Procedimiento para la obtencion de compuestos hidrogenados del acido 1-benzooxacicloalquil-piridincarboxilico.
ES2140765T3 (es) Guanididas sustituidas del acido cinamico, procedimiento para su preparacion, su uso como medicamento o agente de diagnostico cardiovascular, asi como medicamento que las contiene.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
ES2074508T3 (es) Benzocicloalquilaminopiridinaminas y compuestos afines, un procedimiento e intermediarios para su preparacion y su uso como medicamentos.
ES2184424T3 (es) Nuevos compuestos heteroetinilenos y composiciones farmaceuticas y cosmeticas que los contienen.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20110228